VVUS.O on Nasdaq

28 Aug 2015
Change (% chg)

$0.04 (+3.60%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for VVUS.O


VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil)... (more)


Beta: 2.03
Market Cap(Mil.): $119.63
Shares Outstanding(Mil.): 104.02
Dividend: --
Yield (%): --


  VVUS.O Industry Sector
P/E (TTM): -- 35.90 36.13
EPS (TTM): -1.02 -- --
ROI: -35.67 15.37 14.83
ROE: -152.13 15.94 15.69
Search Stocks

Actavis, Vivus clash over in-house counsel role in patent fight

- A U.S. subsidiary of Actavis PLC and rival drugmaker Vivus Inc have asked a federal judge to weigh in on a dispute over whether a Vivus in-house attorney should be allowed to work on a patent lawsuit over Vivus' weight-loss drug Qsymia and on other matters related to that drug at the same time.

06 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC
Provider : Ford Investor Services, Inc.
Provider : Jefferson Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks